In part 2 and the conclusion of our reporting on last week’s Access 2025 meeting, we cover the effect of the new private-label channel in the biosimilar marketplace, implications for the FDA of the Department of Government Efficiency (DOGE)’s early retirement initiative, and other Trump administration actions.    Private Labeling as a Mechanism for Better … Continue reading More Biosimilar Discussions at Access 2025: Private Labeling and New Trump Administration Actions